← Back to Home

An Immune Protein’s Nuclear Role: cGAS Links Cholesterol Metabolism to Cancer Cell Drug Resistance

A study in cells and mice found that cGAS can limit cholesterol synthesis and tumor growth by regulating gene transcription. Restoring this pathway also improved drug responses in experiments, but usable intervention tools and human evidence are still needed before it can become a treatment strategy.

By SURL BioNews

How cancer cells produce and use cholesterol may influence their response to treatment. A University of North Carolina research team found that cGAS, an immune protein best known for detecting abnormal DNA, can also regulate metabolism within the cell nucleus. In experimental models, cancer cells that lost this function accumulated more cholesterol, formed faster-growing tumors, and showed greater resistance to some drugs.

The study was published on November 2 in the Journal of Clinical Investigation and was conducted by Yu Deng and colleagues, with Pengda Liu as senior author. The team combined CUT&RUN, a technique that maps protein distribution across the genome, with RNA sequencing and metabolomic analysis to investigate how cGAS affects gene expression. The results showed that transcription factors in the AP-1 family can recruit nuclear cGAS to specific gene regulatory regions, promoting transcription of the LGALS3 gene. This activity can be separated from the traditional immune alarm function of cGAS.

The subsequent changes unfold along a metabolic chain. Galectin-3, the protein encoded by LGALS3, inhibits ACAA2, an enzyme involved in fatty acid breakdown, reducing the production of acetyl-CoA, which is also a raw material for cholesterol synthesis. When cGAS is absent, this restraint is loosened, cholesterol increases, and mTORC2/Akt signaling, which promotes cell growth, becomes stronger.

The study examined tumor behavior as well as molecular changes. In mouse xenograft models, tumors formed by cancer cells lacking cGAS grew faster. Re-expressing cGAS or LGALS3 reduced cholesterol accumulation and slowed tumor growth. These experiments restoring function allowed the researchers to further confirm a functional link between metabolic changes and tumor behavior.

Evidence on drug responses came mainly from cell experiments. Breast and cervical cancer cells lacking cGAS were less sensitive to the DNA-damaging drugs doxorubicin and etoposide. Sensitivity was restored after cGAS or LGALS3 was re-expressed. The study also observed resistance to some cholesterol-lowering drugs, but these findings cannot yet be extrapolated to patients’ drug responses, nor do they establish that the same mechanism affects all cancer treatments.

Another set of mouse experiments helped clarify the source of the signaling: the Akt inhibitor capivasertib reduced cholesterol accumulation in the livers of mice lacking cGAS, while the STING inhibitor H-151 did not have the same effect. This supports the conclusion that this metabolic activity does not depend on the canonical cGAS–STING immune pathway. However, a reduction in liver cholesterol does not, by itself, demonstrate improved anticancer efficacy.

Both UNC Health and an institutional report published in Medical Xpress quoted Liu as cautioning that it remains unclear whether the cholesterol-related effects extend broadly to other chemotherapy or targeted drugs. The team has also yet to establish a pharmacological intervention targeting this regulatory mechanism. The next step is to find chemical tools to modulate it, followed by validation in animals. The study therefore identifies a drug resistance mechanism for further investigation. Whether it can be translated into a safe and effective treatment remains a question for future research.

References

  1. UNC Health
  2. Journal of Clinical Investigation
  3. Medical Xpress (provided by UNC Lineberger Comprehensive Cancer Center)